# Guardant Health (GH) — Analyst Forecast

GH · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/gh/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 25 | 3 | 1 | 29 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $180.00 | $201.23 | $225.00 | 13 |

Last price $165.88 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 13, 2026 | Morgan Stanley | Maintained | Overweight | $200.00 |
| Oct 7, 2026 | Barclays | Maintained | Overweight | $220.00 |
| Oct 1, 2026 | Guggenheim | Maintained | Buy | $200.00 |
| Sep 9, 2026 | UBS | Maintained | Buy | $225.00 |
| Sep 8, 2026 | Rothschild & Co | Initiated Coverage | Buy | $203.00 |
| Sep 2, 2026 | BTIG | Maintained | Buy | $195.00 |
| Aug 4, 2026 | Stephens & Co. | Maintained | Overweight | $195.00 |
| Aug 4, 2026 | Piper Sandler | Maintained | Overweight | $193.00 |
| Aug 4, 2026 | Morgan Stanley | Maintained | Overweight | $185.00 |
| Aug 3, 2026 | Stifel | Maintained | Buy | $180.00 |
| Jul 31, 2026 | BTIG | Maintained | Buy | $195.00 |
| Jul 31, 2026 | Barclays | Maintained | Overweight | $200.00 |
| Jul 31, 2026 | TD Cowen | Maintained | Buy | $210.00 |
| Jul 31, 2026 | JP Morgan | Maintained | Overweight | $195.00 |
| Jul 31, 2026 | Mizuho | Maintained | Outperform | $200.00 |
| Jul 31, 2026 | RBC Capital | Maintained | Outperform | $200.00 |
| Jul 16, 2026 | Guggenheim | Maintained | Buy | $190.00 |
| Jul 14, 2026 | Canaccord Genuity | Maintained | Buy | $205.00 |
| Jul 9, 2026 | Morgan Stanley | Maintained | Overweight | $175.00 |
| Jul 8, 2026 | Citigroup | Maintained | Buy | $215.00 |

## Frequently Asked Questions

### What is the price target for GH stock?

The average 12-month analyst price target for Guardant Health (GH) is $201.23, with a high estimate of $225.00 and a low of $180.00, across 13 analysts.

### Is GH a buy, sell, or hold?

Analysts covering Guardant Health currently average a Buy rating: 25 buy, 3 hold and 1 sell, from 29 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for GH?

The average price target of $201.23 implies 21.31% upside from the last price of $165.88.

### What is the latest analyst rating on GH?

On Oct 13, 2026, Morgan Stanley maintained Guardant Health at Overweight with a price target of $200.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).